Exelixis (EXEL) | Stock Overview & Key Data

Exelixis Inc. | Healthcare

US$45.40

-1.86%

| Compare Stocks:

Exelixis vs Vertex Exelixis vs Regeneron Exelixis vs Alnylam Exelixis vs Royalty Pharma plc Exelixis vs Insmed Exelixis vs S&P 500 | Market

Exelixis Performance Comparison

Loading chart data...

Exelixis

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: US$45.03 High: US$46.50

on May 16, 2025

52 Week Range

Low: US$20.14 High: US$48.85

on May 29, 2024

on May 15, 2025

All-Time High: US$50.50 on July 10, 2000

Key Statistics

Market Cap i $12.4B

EPS i 2.19

P/E Ratio (TTM) i 20.73

Forward P/E i 26.71

P/B Ratio i 5.86

PEG Ratio i 26.71

Div. Yield i 0.00%

ROE i 30.22%

Beta i 0.248

Debt to Equity i 8.78

Financial Highlights

Profitability

Gross Margin i 96.55%

Operating Margin i 33.64%

Profit Margin i 27.99%

Returns and Earnings

Return on Assets (TTM) i 18.05%

Return on Equity (TTM) i 30.22%

EBITDA i $896.8M

Net Income (TTM) i $643.6M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Exelixis EXEL	12.38B Large-cap	25.52%	25.59%	32.75%	31.52%	33.77%	117.12%	155.63%	84.40%
Vertex VRTX	111.55B Large-cap	3.21%	-9.72%	-5.08%	-6.07%	8.11%	-1.47%	69.63%	53.93%
Regeneron REGN	63.16B Large-cap	12.61%	8.20%	-12.60%	-22.01%	-16.90%	-39.50%	-10.11%	4.28%
Alnylam ALNY	37.20B Large-cap	13.60%	23.78%	14.12%	22.84%	22.13%	90.97%	115.70%	103.04%
Royalty Pharma plc RPRX	18.94B Large-cap	2.62%	5.68%	3.56%	31.86%	31.91%	24.75%	-13.92%	-30.57%
Insmed INSM	12.41B Large-cap	4.67%	-2.96%	-16.27%	2.27%	-2.62%	175.01%	236.40%	165.58%

Ownership & Short Interest

Insider Ownership i 2.26%

Institutional Ownership i 95.84%

Shares Short i 19M

Short Ratio i 7.94

Short % of Shares Outstanding i 9.51%

Average 10-Day Volume i 5M

Average 90-Day Volume i 3M

Exelixis Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Exelixis would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is EXEL's 52-week high and low?

In the last 52 weeks, Exelixis reached a high of US$48.85 (on May 15, 2025) and a low of US$20.14 (on May 29, 2024).

What is the market cap and P/E ratio for EXEL?

Curious about Exelixis's size and valuation? Its market capitalization stands at 12.38B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.73, and the forward P/E (looking ahead) is 26.71.

Does EXEL pay dividends? If so, what's the yield?

As for dividends, Exelixis isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Exelixis's main competitors or similar companies to consider before investing?

When looking at Exelixis, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	111.55B	Healthcare	Biotechnology	-1.47%	69.63%
Regeneron REGN	63.16B	Healthcare	Biotechnology	-39.50%	-10.11%
Alnylam ALNY	37.20B	Healthcare	Biotechnology	90.97%	115.70%
Royalty Pharma plc RPRX	18.94B	Healthcare	Biotechnology	24.75%	-13.92%
Insmed INSM	12.41B	Healthcare	Biotechnology	175.01%	236.40%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Exelixis Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Exelixis's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 30.22%, the Debt to Equity ratio from the most recent quarter is 8.78, and its Gross Profit Margin stands at 96.55%.

What is the recent revenue and earnings growth for EXEL?

Looking at Exelixis's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 30.60%, and quarterly earnings saw a YoY growth of 327.70%.

How much of EXEL stock is held by insiders and institutions?

Wondering who owns Exelixis stock? Company insiders (like executives and directors) hold about 2.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 95.84%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.